Cyclophosphamide-mediated tumor priming for enhanced delivery and antitumor activity of HER2-targeted liposomal doxorubicin (MM-302)

Molecular Cancer Therapeutics

Volumn 14, Issue 9, 2015, Pages 2060-2071

  Geretti, Elena ^a   Leonard, Shannon Curtis ^a   Dumont, Nancy ^a   Lee, Helen ^a   Zheng, Jinzi ^b   De Souza, Raquel ^b   Gaddy, Daniel F ^a   Espelin, Christopher W ^a   Jaffray, David A ^b   Moyo, Victor ^a   Nielsen, Ulrik B ^a   Wickham, Thomas J ^a   Hendriks, Bart S ^a  

^a MERRIMACK PHARMACEUTICALS   (United States)

^b Toronto Medical Discovery Tower   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERIBULIN; IFOSFAMIDE; LIPOSOME; PACLITAXEL; ANTINEOPLASTIC ANTIBIOTIC; MACROGOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DENSITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGE ANALYSIS; MOLECULARLY TARGETED THERAPY; MOUSE; NANOMEDICINE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; HUMAN; METABOLISM; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; IFOSFAMIDE; MICE; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, ERBB-2; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942162856     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0314     Document Type: Article

References (50)

1. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985;43:175-203.
2. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990;9:253-66.
3. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-60.
4. Heldin C-H, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13.
5. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883-6.
6. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 1991;51:6691-4.
7. Gutmann R, Leunig M, Feyh J, Goetz AE, Messmer K, Kastenbauer E, et al. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res 1992;52:1993-5.
8. Less JR, Posner MC, Boucher Y, Borochovitz D, Wolmark N, Jain RK. Interstitial hypertension in human breast and colorectal tumors. Cancer Res 1992;52:6371-4.
9. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-51.
10. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2011;2:281-98.
11. Heine M, Freund B, Nielsen P, Jung C, Reimer R, Hohenberg H, et al. High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. PLoS One 2012;7:e36258.
12. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CYC, Rajasekeran S, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin cancer Res 2007;13:3942-50.
13. Køosowska-Wardega A, Hasumi Y, Burmakin M, Ahgren A, Stuhr L, Moen I, et al. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS One 2009;4:e8149.
14. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
15. Tailor TD, Hanna G, Yarmolenko PS, Dreher MR, Betof AS, Nixon AB. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol Cancer Ther 2010;159:1798-808.
16. Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012;7:383-8.
17. Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. PNAS 2011;108:2909-14.
18. Liu J, Liao S, Diop-Frimpong B, Chen W, Goel S, Naxerova K, et al. TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. PNAS 2012;109:16618-23.
19. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21:418-29.
20. Yu M, Tannock IF. Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? Cancer Cell 2012;21:327-9.
21. Eikenes L, Tari M, Tufto I, Bruland OS, de Lange Davies C. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br J Cancer 2005;93:81-8.
22. Kohli AG, Kivimäe S, Tiffany MR, Szoka FC. Improving the distribution of Doxil® in the tumor matrix by depletion of tumor hyaluronan. J Control Release 2014;191:105-14.
23. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature 2004;427:695.
24. Stylianopoulos T, Jain RK. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A 2013;110:18632-7.
25. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999;59:3776-82.
26. Lu D, Wientjes MG, Lu Z, Au JL-S. Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther 2007;322:80-8.
27. Ishida T, Shiraga E, Kiwada H. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model. J Control Release 2009;134:194-200.
28. Martín M, Sánchez-Rovira P, Muñoz M, Baena-Cañada JM, Mel JR, Margeli M, et al. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Ann Oncol 2011;22:2591-6.
29. Rayson D, Suter TM, Jackisch C, van der Vegt S, Bermejo B, van den Bosch J, et al. Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Ann Oncol 2012;23:1780-8.
30. Trudeau ME, Clemons MJ, Provencher L, Panasci L, Yelle L, Rayson D, et al. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. J Clin Oncol 2009;27:5906-10.
31. Hendriks BS, Reynolds JG, Klinz SG, Geretti E, Lee H, Leonard SC, et al. Multiscale kinetic modeling of liposomal doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors. CPT Pharmacometrics Syst Pharmacol 2012;1:e15.
32. Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Klinz SG, et al. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol Appl Pharmacol 2012;262:1-10.
33. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66:6732-40.
34. Ozerdem U, Hargens AR. A simple method for measuring interstitial fluid pressure in cancer tissues. Microvasc Res 2005;70:116-20.
35. Lee H, Zheng J, Gaddy D, Orcutt KD, Leonard S, Geretti E, et al. A gradient-loadable (64)Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography. Nanomedicine 2015;11:155-65.
36. Onsum MD, Geretti E, Paragas V, Kudla AJ, Moulis SP, Luus L, et al. Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients. Am J Pathol 2013;183:1446-60.
37. Reed RK, Berg A, Gjerde EA, Rubin K. Control of interstitial fluid pressure: role of beta1-integrins. Semin Nephrol 2001;21:222-30.
38. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006;2:458-66.
39. Wickham T FK. A phase i study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2- positive breast cancer. J Clin Oncol 30, 2012 (suppl; abstr TPS663).
40. Munster P, Krop IE, Miller K, Dhindsa N, Niyijiza C, Nielsen U, et al. Assessment of safety and activity in an expanded phase 1 study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced HER2-positive (HER2+) breast cancer. San Antonio Breast Cancer Symposium, Dec 10-14, 2013. Poster P4-12-29 SABCS 2013.
41. Amos KD, Adamo B, Anders CK. Triple-negative breast cancer: an update on neoadjuvant clinical trials. Int J Breast Cancer 2012;2012:385978.
42. Cortazar P, Justice R, Johnson J, Sridhara R, Keegan P, Pazdur R. US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol 2012;30:1705-11.
43. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
44. Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N, et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. PNAS 2012;109:15101-8.
45. Potamianou A, Androulakis N, Papakotoulas P, Toufexi H, Latoufis C, Kouroussis C, et al. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer: a multicenter phase II trial. Oncology 2005;69:348-53.
46. Briasoulis E, Karavasilis V, Tzamakou E, Rammou D, Soulti K, Piperidou C, et al. Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Cancer Chemother Pharmacol 2004;53:452-7.
47. De la Fouchardiere C, Largillier R, Goubely Y, Hardy-Bessard A-C, Slama B, Cretin J, et al. Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE. Ann Oncol 2009;20:1959-63.
48. Gabizon AA, Shmeeda H, Grenader T. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. Eur J Pharm Sci 2012;45:388-98.
49. Fan Y, Lin N, Luo L, Fang L, Huang Z, Yu H, et al. Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. Acta Pharmacol Sin 2011;32:408-14.
50. Nielsen OS, Reichardt P, Christensen TB, Pink D, Daugaard S, Hermans C, et al. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Eur J Cancer 2006;42:2303-9.